Apixaban on par with dalteparin in reducing VTE recurrence in cancer
22 Apr 2020
byRoshini Claire Anthony
Patients with cancer who develop venous thromboembolism (VTE) could reduce their risk of VTE recurrence with the direct oral anticoagulant (DOAC) apixaban, which demonstrated noninferiority to subcutaneous dalteparin in the Caravaggio* trial.
Apixaban on par with dalteparin in reducing VTE recurrence in cancer
22 Apr 2020
